Senhwa’s pidnarulex receives US FDA fast track designation for the treatment of solid tumours with BRCA1/2, PALB2 and other HR gene mutations

Senhwa Biosciences

24 January 2022 - Senhwa Biosciences announced today that the US FDA has granted fast track designation for Pidnarulex, a first in class G quadruplex stabiliser, for the treatment of patients with breast and ovarian cancers BRCA1/2, PALB2, or other HRD mutations.

Currently, pidnarulex is tested in a Phase 1b open label, multicentre expansion study (in both US and Canada) to determine a tolerable dose in patients with selected solid tumours with BRCA2 and PALB2, and ovarian cancer with BRCA1 and other HR gene mutations.

Read Senhwa Biosciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track